Related Experiment Videos
Coagulation inhibitors in sepsis and disseminated intravascular coagulation
1Toronto General Hospital of the University Health Network, Department of Medicine, Ontario, Canada.
Insights
Sepsis and its complication, disseminated intravascular coagulation (DIC), have high mortality. Novel therapies like antithrombin III show promise but require further study to confirm survival benefits in sepsis patients.
Area of Science:
- Critical Care Medicine
- Hematology
- Infectious Diseases
Background:
- Sepsis is a life-threatening syndrome with increasing incidence and high mortality rates.
- Disseminated intravascular coagulation (DIC) frequently complicates sepsis, contributing to organ failure and poor prognosis.
- Understanding sepsis-induced DIC pathogenesis has led to the exploration of novel coagulation inhibitor therapies.
Purpose of the Study:
- To review the current understanding and emerging therapies for sepsis-associated disseminated intravascular coagulation (DIC).
- To evaluate the evidence for novel treatments targeting coagulation deficiencies in sepsis and DIC.
- To highlight the need for further clinical trials to establish the efficacy of these novel therapies.
Main Methods:
- Review of existing literature on sepsis, DIC, and novel therapeutic agents.
- Analysis of small randomized controlled studies of antithrombin III concentrates in sepsis and DIC.
- Discussion of ongoing large-scale clinical trials and preliminary findings from animal models.
Main Results:
- Small studies of antithrombin III (AT-III) for sepsis and DIC show a trend towards improved survival, but lack statistical significance.
- Therapies with protein C and tissue factor-pathway inhibitor have demonstrated efficacy in animal models of sepsis and DIC.
- A large randomized controlled trial of AT-III in sepsis is currently underway.
Conclusions:
- Novel therapies targeting coagulation deficiencies, such as antithrombin III, protein C, and tissue factor-pathway inhibitor, hold potential for treating sepsis and DIC.
- Current evidence for antithrombin III is inconclusive, necessitating results from ongoing large clinical trials.
- The role of these novel agents in managing sepsis, septic shock, and DIC remains to be definitively established pending human clinical trial outcomes.
Abstract:
Sepsis is a syndrome that is increasing in frequency and continues to be associated with an unacceptably high mortality. DIC is an important and common sequel of sepsis, is implicated in the development of multiple organ failure, and has been shown repeatedly to connote a poor prognosis. Increasing understanding of the pathogenesis of DIC has suggested several novel therapies designed to correct deficiencies in inhibitors of coagulation. To date, small randomized, controlled studies of antithrombin III concentrates in sepsis and DIC have shown a trend to increased survival, but have not achieved statistical significance. Currently, a large randomized controlled trial of antithrombin III in sepsis is being conducted. Until more data are available, important questions remain as to its proper place in the treatment of sepsis, septic shock, and DIC. Similarly, therapy with protein C and tissue factor-pathway inhibitor has been beneficial in animal models of sepsis and DIC. The results of controlled clinical trials in humans are eagerly awaited.